Arrowhead Pharmaceuticals reports strong ARO-MAPT phase 1 results, plans multiple CNS trials by 2027

Arrowhead Pharmaceuticals exceeded expectations with its ARO-MAPT phase 1 trial, achieving up to 85% reduction in CSF tau protein, validating its CNS siRNA platform. The company plans to expand its central nervous system (CNS) pipeline by starting two new phase 2 trials for ARO-MAPT and advancing four other CNS candidates into clinical trials by the end of 2027. Recent successes include positive phase 3 data for Redemplo and entry into the FDA STAR program, supporting a strong growth outlook. With $1.6 billion in cash, Arrowhead is well-positioned to launch Redemplo for SHTG and continue investing in its pipeline, though near-term commercial execution remains a risk.

Arrowhead Pharmaceuticals shares are trading at USD 58.51 on Pluang, showing a modest 0.24% increase in the last day. As of Oct 15, 2026 19:42 WIB, the stock's market cap stands at $8.25 billion with a trading volume of over 4 million shares.